Long-term 4CMenB Vaccine Effectiveness Against Gonococcal Infection at Four Years Post–Program Implementation: Observational Case–Control Study
4CMenB demonstrates moderate effectiveness against gonococcal infection, with a lower VE estimate after 4 years postvaccination. 4CMenB may reduce the risk of recurrent gonococcal infection. The requirement for a booster dose and dosing interval warrants evaluation.
Authors
- Mark McMillan (ORCID: https://orcid.org/0000-0002-6490-7707)
- James Ward (ORCID: https://orcid.org/0000-0002-2892-4542)
- Janine Mitchell (ORCID: https://orcid.org/0000-0003-0781-3111)
- Rebecca Beazley
- Jana Sisnowski
- Prabha H. Andraweera (ORCID: https://orcid.org/0000-0003-2434-8370)
- Sara Almond
- Noel Lally
- Lynne Giles (ORCID: https://orcid.org/0000-0001-9054-9088)
- Bing Wang (ORCID: https://orcid.org/0000-0003-2445-2952)
- Charlotte Bell (ORCID: https://orcid.org/0009-0008-4140-5369)
- Helen Siobhan Marshall (ORCID: https://orcid.org/0000-0003-2521-5166)
- Louise Flood (ORCID: https://orcid.org/0000-0001-6771-1657)
Institutions
- The University of Queensland (AU)
- Women's and Children's Health Network (AU)
- SA Health (AU)
- The University of Adelaide (AU)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2024-12-13
- DOI
- https://doi.org/10.1093/ofid/ofae726
- Citations
- 8
- Primary Topic
- Reproductive tract infections research
- Type
- article
- Field-Weighted Citation Impact
- 2.76
Funders
- Australian Government
- Department of Health and Aged Care, Australian Government
- Medical Research Council
- National Health and Medical Research Council